日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

TCHL - a phase II neo-adjuvant study assessing TCH (docetaxel, carboplatin and trastuzumab) and TCHL (docetaxel, carboplatin, trastuzumab and lapatinib) in HER-2 positive breast cancer patients: a 5-year follow-up with serum biomarker analysis

TCHL——一项评估TCH(多西他赛、卡铂和曲妥珠单抗)和TCHL(多西他赛、卡铂、曲妥珠单抗和拉帕替尼)方案在HER-2阳性乳腺癌患者中疗效的II期新辅助治疗研究:一项为期5年的随访研究及血清生物标志物分析

Crown, John; Eustace, Alex J; Collins, Denis M; Keane, Maccon; Coate, Linda; Kennedy, John; O'Reilly, Seamus; Kelly, Catherine; O'Connor, Miriam; Martin, Michael; Murphy, Conleth; Duffy, Karen; Walshe, Janice; Gullo, Giuseppe; Mahgoub, Thamir; Alvarez-Iglesias, Alberto; Parker, Imelda; Donachie, Vicky; Teiserskiene, Ausra; Madden, Stephen F; Moulton, Brian; O'Donovan, Norma; Hennessy, Bryan T

Mirvetuximab soravtansine in folate receptor alpha (FRα)-high platinum-resistant ovarian cancer: final overall survival and post hoc sequence of therapy subgroup results from the SORAYA trial

在叶酸受体α (FRα) 高表达的铂类耐药卵巢癌中,Mirvetuximab soravtansine 的最终总生存期和 SORAYA 试验的事后治疗顺序亚组结果

Coleman, Robert L; Lorusso, Domenica; Oaknin, Ana; Cecere, Sabrina Chiara; Denys, Hannelore; Colombo, Nicoletta; van Gorp, Toon; Konner, Jason A; Romeo Marin, Margarita; Harter, Philipp; Murphy, Conleth; Wang, Yuemei; Esteves, Brooke; Method, Michael; Matulonis, Ursula

Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study

Mirvetuximab Soravtansine治疗铂耐药且叶酸受体α高表达的卵巢癌患者的疗效和安全性:SORAYA研究结果

Matulonis, Ursula A; Lorusso, Domenica; Oaknin, Ana; Pignata, Sandro; Dean, Andrew; Denys, Hannelore; Colombo, Nicoletta; Van Gorp, Toon; Konner, Jason A; Marin, Margarita Romeo; Harter, Philipp; Murphy, Conleth G; Wang, Jiuzhou; Noble, Elizabeth; Esteves, Brooke; Method, Michael; Coleman, Robert L

Inborn Errors of Immunity on the Island of Ireland - a Cross-Jurisdictional UKPID/ESID Registry Report

爱尔兰岛先天性免疫缺陷——英国先天性免疫缺陷病/欧洲免疫缺陷病跨辖区登记报告

Ryan, Paul; Redenbaugh, Vyanka; McGucken, Jayne; Kindle, Gerhard; Devlin, Lisa A; Coulter, Tanya; Buckland, Matthew S; Seppänen, Mikko R J; Conlon, Niall P; Feighery, Conleth; Edgar, J David M

Correction to: Inborn Errors of Immunity on the Island of Ireland - a Cross‑Jurisdictional UKPID/ESID Registry Report

更正:爱尔兰岛先天性免疫缺陷——英国先天性免疫缺陷病/欧洲免疫缺陷病跨辖区登记报告

Ryan, Paul; Redenbaugh, Vyanka; McGucken, Jayne; Kindle, Gerhard; Devlin, Lisa A; Coulter, Tanya; Buckland, Matthew S; Seppänen, Mikko R J; Conlon, Niall P; Feighery, Conleth; Edgar, J David M

Recent Progress and Recommendations on Celiac Disease From the Working Group on Prolamin Analysis and Toxicity

乳糜泻研究进展及建议——来自醇溶蛋白分析与毒性工作组

Scherf, Katharina A; Catassi, Carlo; Chirdo, Fernando; Ciclitira, Paul J; Feighery, Conleth; Gianfrani, Carmen; Koning, Frits; Lundin, Knut E A; Schuppan, Detlef; Smulders, Marinus J M; Tranquet, Olivier; Troncone, Riccardo; Koehler, Peter

Statement of the Prolamin Working Group on the Determination of Gluten in Fermented Foods Containing Partially Hydrolyzed Gluten

关于测定含部分水解麸质发酵食品中麸质含量的醇溶蛋白工作组声明

Scherf, Katharina Anne; Catassi, Carlo; Chirdo, Fernando G; Ciclitira, Paul J; Feighery, Conleth Francis; Gianfrani, Carmen; Koning, Frits; Lundin, Knut E A; Masci, Stefania; Schuppan, Detlef; Smulders, Marinus J M; Tranquet, Olivier; Troncone, Riccardo; Koehler, Peter

PARP Inhibitors in Clinical Use Induce Genomic Instability in Normal Human Cells

临床使用的PARP抑制剂会诱导正常人类细胞基因组不稳定

Ito, Shuhei; Murphy, Conleth G; Doubrovina, Ekaterina; Jasin, Maria; Moynahan, Mary Ellen

Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis caused by gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation

使用芦可替尼成功治疗因获得功能信号转导和转录激活因子 1 (STAT1) 突变引起的慢性皮肤粘膜念珠菌病

Eleanor Higgins, Tariq Al Shehri, Maeve A McAleer, Niall Conlon, Conleth Feighery, Desa Lilic, Alan D Irvine

The Role of CDK4/6 Inhibition in Breast Cancer

CDK4/6抑制在乳腺癌中的作用

Murphy, Conleth G; Dickler, Maura N